Selçuk Ecza Deposu stock (TRASELEC91C3): Q1 2026 sales up 15% YoY

Selçuk Ecza Deposu, a leading pharmaceutical wholesaler in Turkey, released its first-quarter 2026 earnings on May 12, 2026, showing revenue growth of 15% compared to the prior year, according to Ad-hoc-news.de as of 12.05.2026. The company, which supplies about 30% of Turkey's pharmacy market, operates a network of regional depots for efficient distribution to pharmacies and hospitals. Shares (SELEC) traded at 79.80 TRY on Borsa Istanbul, down 8.28% from the previous close, with a daily range of 78.50-86.05 TRY, per Mynet Finans.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Selçuk Ecza Deposu: core business model

Selçuk Ecza Deposu focuses on wholesale distribution of pharmaceuticals and health products across Turkey. The company maintains a logistics network with multiple regional depots, enabling efficient supply to approximately 30% of the nation's pharmacies, clinics, and hospitals, as noted in company profiles from Ad-hoc-news.de as of 12.05.2026. It procures medications from international and local manufacturers for resale.

In 2025, full-year revenue reached around 25 billion TRY for the period January 1 to December 31, 2025, published March 15, 2026 per IR reports cited in the same source. This underscores its dominant position in Turkey's pharma distribution sector.

Main revenue and product drivers for Selçuk Ecza Deposu

Primary revenue stems from distributing prescription drugs, over-the-counter medicines, and health products to retail pharmacies and healthcare facilities. The company's scale provides leverage in supplier negotiations and logistics cost efficiencies. Q1 2026 revenue grew 15% year-over-year, reflecting steady demand in Turkey's healthcare market, according to the earnings release dated May 12, 2026 via Ad-hoc-news.de as of 12.05.2026.

Key drivers include population growth, rising healthcare needs, and government-regulated pricing in Turkey's pharma sector. The stock closed at 79.80 TRY on May 13, 2026, after an 8.28% decline, as reported by Mynet Finans.

Why Selçuk Ecza Deposu matters for US investors

US investors may find exposure to Selçuk Ecza Deposu appealing for diversification into emerging market healthcare, particularly Turkey's pharma distribution oligopoly. With a 28-30% market share, it benefits from stable demand tied to demographics and healthcare spending. Listing on Borsa Istanbul (TRASELEC91C3) allows access via international brokers, offering a play on regional growth without direct Turkey equity risks.

Conclusion

Selçuk Ecza Deposu's Q1 2026 results highlight resilient revenue growth amid Turkey's healthcare demands, despite a recent share price dip. The company's market leadership positions it well in pharma wholesaling. Investors tracking emerging market pharma should monitor upcoming quarters for sustained trends and currency impacts from TRY volatility.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.